Zhengda Tianqing Reorganization of Human Coagulation Factor VIIa Approved for Listing on the Market

The first domestically produced recombinant human coagulation factor VIIa biological product has been approved for market. On July 3rd, Yabao Pharmaceutical Group received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the injection of recombinant human coagulation factor VIIa N01 for the treatment of bleeding in adult and adolescent patients with congenital hemophilia A with factor VIII or factor IX inhibitors greater than 5 Bethesda units.